| http://www.w3.org/ns/prov#value | - However, in the ticagrelor group, there was a higher rate of non-CABG-related major bleeding according to the study criteria (4.5% vs. 3.8%, P=0.03) and the TIMI criteria (2.8% vs. 2.2%, P=0.03).Moreover, the ticagrelor group had a higher incidence of intracranial bleeding [26 (0.3%) vs. 14 (0.2%), P=0.06], including fatal intracranial bleeding [11 (0.1%) vs. 1 (0.01%), P=0.02].
|
